Lexicon Pharmaceuticals Inc
LXRX1.155USD
+0.085+7.94%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
419.47MCap. mercado
PérdidaP/E TTM
Más Datos de Lexicon Pharmaceuticals Inc Compañía
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Información de la empresa
Símbolo de cotizaciónLXRX
Nombre de la empresaLexicon Pharmaceuticals Inc
Fecha de salida a bolsaApr 07, 2000
Director ejecutivoMr. Michael Exton
Número de empleados103
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 07
Dirección2445 Technology Forest Blvd
CiudadTHE WOODLANDS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77381
Teléfono12818633000
Sitio Webhttps://www.lexpharma.com/
Símbolo de cotizaciónLXRX
Fecha de salida a bolsaApr 07, 2000
Director ejecutivoMr. Michael Exton
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Dr. Judith L. Swain, M.D.
Dr. Judith L. Swain, M.D.
Independent Director
Independent Director
85.17K
+76.11%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Independent Director
Independent Director
36.81K
--
Ms. Wendy E. Mcdermott
Ms. Wendy E. Mcdermott
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ms. Kristen L. Alexander
Ms. Kristen L. Alexander
Vice President - Finance and Accounting
Vice President - Finance and Accounting
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
Accionistas
Accionistas
Proporción
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
68.24%
Hedge Fund
3.93%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
1.23%
Research Firm
0.50%
Family Office
0.06%
Bank and Trust
0.05%
Pension Fund
0.01%
Other
22.25%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
320
282.21M
77.71%
-40.09M
2025Q1
325
276.43M
76.32%
-62.57M
2024Q4
309
308.33M
85.37%
-6.09M
2024Q3
300
300.67M
83.18%
-4.62M
2024Q2
291
290.96M
80.51%
+37.02M
2024Q1
279
184.47M
74.41%
-20.75M
2023Q4
274
194.11M
79.36%
-11.88M
2023Q3
271
200.84M
82.07%
-4.66M
2023Q2
276
200.76M
82.17%
+43.01M
2023Q1
274
154.64M
82.03%
-4.81M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Artal International S.C.A.
136.18M
37.5%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
38.92M
10.72%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
34.54M
9.51%
-17.43M
-33.53%
Mar 31, 2025
The Vanguard Group, Inc.
9.56M
2.63%
-278.32K
-2.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.21M
2.54%
-237.79K
-2.52%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
8.21M
2.26%
+654.37K
+8.66%
Mar 31, 2025
Ulys, L.L.C.
5.45M
1.5%
--
--
Dec 05, 2024
Geode Capital Management, L.L.C.
3.69M
1.02%
+168.02K
+4.77%
Mar 31, 2025
GSA Capital Partners LLP
807.49K
0.22%
+807.49K
--
Mar 31, 2025
State Street Global Advisors (US)
2.61M
0.72%
-110.67K
-4.07%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0%
Texas Capital Texas Equity Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.68%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0%
Texas Capital Texas Equity Index ETF
Proporción0%
Goldman Sachs Innovate Equity ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
